Natera up 1% on Medicare reimbursement for Prospera test

Mar. 03, 2020 10:02 AM ETNatera, Inc. (NTRA)NTRABy: Douglas W. House, SA News Editor
  • Natera (NTRA +1.1%) shrugs of the broad market selling, albeit on light volume, after announcing that Medicare will reimburse $2,840.75 for its Prospera donor-derived cell-free DNA test designed to detect clinical and subclinical rejection in organ transplant patients.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.